Home
NewsNewsMemphasys Felix Qatar IVF orders secure Hamad Medical Corporation as a reference customer, driving robust cartridge demand, accelerating widespread IVF adoption across the MENA region, and establishing crucial clinical credibility for future expansion.
Memphasys Felix Qatar IVF orders entered a commercial execution phase after Hamad Medical Corporation (HMC) began routine clinical purchasing of Felix™ cartridges in Qatar. HMC, the country’s largest public healthcare provider and leading IVF service, is now ordering approximately 100 cartridges per month, supporting close to 1,500 IVF cycles annually and creating a recurring institutional demand profile.
The agreement marks Memphasys’ first large-scale institutional customer in the Middle East and North Africa and follows CE Mark approval, which allows Felix™ to be used immediately across Qatar and other CE-recognised MENA markets. The deployment is being executed under Memphasys’ go-direct commercial strategy with distribution partner International Technical Legacy.
HMC’s projected annual usage of roughly 1,200 cartridges represents almost half of International Technical Legacy’s minimum annual commitment of 2,500 cartridges, significantly de-risking contracted volumes. This single institutional adoption also establishes a high-credibility reference point for Memphasys Felix Qatar IVF orders as the company targets broader uptake across the region’s estimated 350 IVF clinics.
Felix™ is positioned as an alternative to centrifugation-based sperm preparation, which can expose sperm cells to mechanical stress and DNA damage. The system uses a patented bioseparation process combining electrophoresis and size-exclusion membranes to isolate viable sperm with reduced cellular stress, faster laboratory workflows and more standardised results across operators.
Outside of Qatar, Memphasys has also received a follow-on order of 200 cartridges from International Technical Legacy (ITL), representing demand from clinics across the UAE and neighbouring regions. Memphasys is in late-stage commercial discussions with clinics in five other countries, looking to expand into those markets in the short-term.
Egypt will be another focus market for Memphasys expansion, with demand for IVF therapies expected to reach over USD 500 million. To continue supporting growth in the region, Memphasys’ A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth, will undertake his second partner-funded visit to the region. He will be working with HMC to optimise usage, onboard clinics rapidly and meet with clinicians at a large ART conference taking place in Egypt.
Together, the HMC deployment and follow-on regional orders demonstrate that Felix™ is transitioning from evaluation to routine clinical use. The cartridge-based consumable model supports recurring revenue, while institutional adoption provides validation that extends beyond a single customer win.
Pulsenmore has completed MHRA registration of Pulsenmore FC, entering the UK fertility market with its patient-operated home ultrasound system for follicular and endometrial monitoring during IVF and fertility preservation treatments. The move follows CE European registration and targets a UK market where over 100,000 fertility treatment cycles were performed in 2024.
Memphasys has confirmed a Felix System Nordic expansion into Denmark, Sweden, Norway, Finland, and Iceland through an exclusive agreement with fertility-technology distributor NOVIVITAE ApS. The deal carries minimum contracted purchases of €526,500 across three years, with an initial order of €20,625 and three Felix™ consoles to be supplied in the September 2026 quarter.
India's Central Drugs Standard Control Organisation has overhauled CDSCO IVF reagent sale norms, directing that all ART media, culture solutions, and reagents be supplied exclusively to clinics registered under the ART (Regulation) Act and Surrogacy (Regulation) Act. The move targets a growing unlicensed supply chain feeding an estimated 40–50% of India's 2,000-plus IVF centres.
Abu Dhabi University and FertiClinic Group have joined forces to establish the FertiClinic Reproductive Research Lab, an advanced reproductive research lab in Abu Dhabi housing IVF, andrology, and cryopreservation facilities. The partnership supports UAE national priorities, bridges academic and clinical expertise, and advances fertility innovation across the region.
NHS Kent and Medway has overhauled its fertility funding policy in a move that sees NHS cuts IVF access for thousands of patients. Effective 1 April 2026, the eligible age ceiling drops from 40 to 38, funded cycles fall from two to one, and embryo transfers are capped at two.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
CSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
